Sanofi Ends Drug Program After Late-Stage Trial in Lung Cancer Fails
By Adria Calatayud
Sanofi said it would end a clinical-development program for its tusamitamab ravtansine drug candidate after a late-stage trial in previously treated patients with nonsmall cell lung cancer didn't meet its primary goal.
The French pharmaceutical company said the decision came after an independent data monitoring committee found that tusamitamab ravtansine as a monotherapy didn't meet its primary goal of progression-free survival compared to docetaxel. The trial had dual primary goals of progression-free survival and overall survival.
While overall survival improved, the decision on the trial was based on a lack of improvement on progression-free survival, Sanofi said Thursday.
Tusamitamab ravtansine had a similar safety profile as previously presented, the company said.
Sanofi said it will continue exploring the potential of tusamitamab-based antibody drug conjugates and research on the potential of certain molecules as biomarkers in several types of cancer.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
December 21, 2023 02:10 ET (07:10 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings, Is Disney Stock a Buy, a Sell, or Fairly Valued?
-
Home Depot Earnings: Macro Factors Pinch Demand, but Long-Term Outlook Intact
-
Tariffs On Chinese EVs Offer US Automakers a Chance to Capture Demand
-
The Best REITs to Buy
-
3 Hot Stocks to Buy That Still Look Undervalued
-
After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks